REV-ERB is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-29. Numbers and descriptions here follow the published literature rather than marketing material.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
=== Non-ribosomal peptide synthase === The non-ribosomal peptide synthase (NRPS) is encoded by three genes: CepA, CepB, and CepC. CepA links the first three amino acids; CepB adds the fourth to sixth amino acids; CepC adds the last amino acid and includes a thioesterase domain to release the heptapeptide from the NRPS complex. The growing peptide chain is passed through modules for each amino acid. The basic organization of each module is A-PCP-C. The A, or adenylation, region activates the domain's amino acid to allow transfer to the PCP, or peptide carrying protein, region. The activated amino acid is transferred to a cysteine residue in the PCP region, which anchors the amino acid and prepares the amino acid to be added to the polypeptide. The C, or condensation, region attaches the amino acid to the polypeptide. In addition, modules 2, 4, and 5 have E regions that epimerize (switch the stereochemistry) of the added amino acid to produce the correct configuration. Module 7, the last module, has an X and TE region. The X region is responsible for recruiting several of the tailoring enzymes that will perform the necessary reactions (halogenation, glycosylation, methylation, oxidative cross-linking, and hydroxylations) to produce chloroeremomycin. Finally, the TE, or thioesterase, region releases chloroeremomycin from the NRPS complex.
== In vivo vs In vitro == In vivo staining (also called vital staining or intravital staining) is the process of dyeing living tissues. By causing certain cells or structures to take on contrasting colours, their form (morphology) or position within a cell or tissue can be readily seen and studied. The usual purpose is to reveal cytological details that might otherwise not be apparent; however, staining can also reveal where certain chemicals or specific chemical reactions are taking place within cells or tissues. In vitro staining involves colouring cells or structures that have been removed from their biological context. Certain stains are often combined to reveal more details and features than a single stain alone. Combined with specific protocols for fixation and sample preparation, scientists and physicians can use these standard techniques as consistent, repeatable diagnostic tools. A counterstain is stain that makes cells or structures more visible, when not completely visible with the principal stain.
=== Aerobic Exercise === Aerobic exercise is also known as cardio because it is a form of cardiovascular conditioning. This includes exercises such as running, cycling, swimming and rowing. Athletes involved in aerobic exercise are typically looking to increase their endurance. These athletes are training their slow twitch muscle fibers to be better at taking in oxygen and getting it to their muscles. This is done by two mechanisms, glycolysis and aerobic respiration. Anaerobic glycolysis is also referred to as the "short term energy system", and is mostly used for high-intensity training, such as sprinting, and any sports which require quick bursts of speed. Slow twitch muscles are smaller in diameter and are slow to contract. These fibers don't store much glycogen, instead they use lipids and amino acids to generate energy. It has been shown that amino acids contributed around 3% of the total energy expenditure during endurance exercise. With a high concentration of myoglobin that stores oxygen, the slow twitch muscle fibers have plenty of oxygen to function properly. These factors help make slow twitch muscle fibers fatigue resistant so athletes can have endurance in their sport. There are many options for supplements that athletes can take to assist with endurance like glycerol and guarana.
Cigarette tubes are prerolled cigarette paper usually with an acetate or paper filter at the end. They have an appearance similar to a finished cigarette, but do not contain any tobacco or smoking material inside, as the consumer is intended to fill the tube themself. They may vary in length from regular (70 mm) to king size (84 mm) as well as 100s (100 mm) and 120s (120 mm). Cigarette tubes are usually filled with a cigarette injector (also known as a shooter). Cone-shaped cigarette tubes, known as cones, can be filled using a packing stick or straw because of their shape. Cone smoking is popular because as the cigarette burns, it tends to get stronger and stronger. This is because the cone shape allows more tobacco to be burned at the beginning than the end, allowing for an even flavor. The United States Tobacco Taxation Bureau defines a cigarette tube as "cigarette paper made into a hollow cylinder for use in making cigarettes."
=== Immobilized metal ion affinity chromatography === Immobilized metal ion affinity chromatography (IMAC) is based on the specific coordinate covalent bond of amino acids, particularly histidine, to metals. This technique works by allowing proteins with an affinity for metal ions to be retained in a column containing immobilized metal ions, such as cobalt, nickel, or copper for the purification of histidine-containing proteins or peptides, iron, zinc or gallium for the purification of phosphorylated proteins or peptides. Many naturally occurring proteins do not have an affinity for metal ions, therefore recombinant DNA technology can be used to introduce such a protein tag into the relevant gene. Methods used to elute the protein of interest include changing the pH, or adding a competitive molecule, such as imidazole.
Sources: en.wikipedia.org
{\displaystyle (\mathbf {u} _{1}\times \mathbf {u} _{2})\times (\mathbf {u} _{2}\times \mathbf {u} _{3})=[(\mathbf {u} _{2}\times \mathbf {u} _{3})\cdot \mathbf {u} _{1}]\mathbf {u} _{2}-[(\mathbf {u} _{2}\times \mathbf {u} _{3})\cdot \mathbf {u} _{2}]\mathbf {u} _{1}=[(\mathbf {u} _{2}\times \mathbf {u} _{3})\cdot \mathbf {u} _{1}]\mathbf {u} _{2}}
Han Chinese who committed crimes such as those dealing with opium became slaves to the begs, this practice was administered by Qing law. Most Chinese in Altishahr were exile slaves to Turkestani Begs. While free Chinese merchants generally did not engage in relationships with East Turkestani women, some of the Chinese slaves belonging to begs, along with Green Standard soldiers, Bannermen, and Manchus, engaged in affairs with the East Turkestani women that were serious in nature.
== Aquaculture == Thailand was the world's tenth ranked aquaculture producer in 2015, having produced 0.9 million tonnes. Other ASEAN nations among the top ten were ranked: Indonesia, 3; Vietnam, 4; Myanmar, 9.
== Societies == The more empirical approach to human and medical genetics was formalized by the founding in 1948 of the American Society of Human Genetics. The Society first began annual meetings that year (1948) and its international counterpart, the International Congress of Human Genetics, has met every 5 years since its inception in 1956. The Society publishes the American Journal of Human Genetics on a monthly basis. Medical genetics is recognized as a distinct medical specialty. In the U.S., medical genetics has its own approved board (the American Board of Medical Genetics) and clinical specialty college (the American College of Medical Genetics). The college holds an annual scientific meeting, publishes a monthly journal, Genetics in Medicine, and issues position papers and clinical practice guidelines on a variety of topics relevant to human genetics. In Australia and New Zealand, medical geneticists are trained and certified under the auspices of the Royal Australasian College of Physicians, but professionally belong to the Human Genetics Society of Australasia and its special interest group, the Australasian Association of Clinical Geneticists, for ongoing education, networking and advocacy.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.